Ovation® pipettes have a unique and patented ergonomic design. They are the only pipettes that fully address the issues of posture, repetition, and force to significantly reduce strain and pain that occur from pipetting, while always providing
Ovation® pipettes have a unique and patented ergonomic design. They are the only pipettes that fully address the issues of posture, repetition, and force to significantly reduce strain and pain that occur from pipetting, while always providing
The Ovation®: offers superior accuracy and precision with unmatched patented ergonomic design. <br><br>•: Audible click tip attachment to ensure consistent loading<br>•: Easy spring-loaded flick tip ejection for low thumb
The Ovation®: offers superior accuracy and precision with unmatched patented ergonomic design. <br><br>•: Audible click tip attachment to ensure consistent loading<br>•: Easy spring-loaded flick tip ejection for low thumb
Biochem/physiol Actions Anle138b is a fluorescent inhibitor of α:-synuclein and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′:s disease in animal models. Anle138b extends the survival of mice
Biochem/physiol Actions Anle138b is a fluorescent inhibitor of α:-synuclein and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′:s disease in animal models. Anle138b extends the survival of mice
Biochem/physiol Actions Anle138b is a fluorescent inhibitor of α:-synuclein and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′:s disease in animal models. Anle138b extends the survival of mice
Biochem/physiol Actions Anle138b is a fluorescent inhibitor of α:-synuclein and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′:s disease in animal models. Anle138b extends the survival of mice
Biochem/physiol Actions E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α:2. E7820 promotes selective
Biochem/physiol Actions E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α:2. E7820 promotes selective
Biochem/physiol Actions E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α:2. E7820 promotes selective
Biochem/physiol Actions E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α:2. E7820 promotes selective